1. Market Research
  2. > Other Dermatological Disorders – Pipeline Review, H1 2013

Other Dermatological Disorders – Pipeline Review, H1 2013

  • March 2013
  • -
  • Global Markets Direct
  • -
  • 41 pages

Other Dermatological Disorders – Pipeline Review, H1 2013

Summary

Global Markets Direct’s, 'Other Dermatological Disorders - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Other Dermatological Disorders, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Other Dermatological Disorders. Other Dermatological Disorders - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Other Dermatological Disorders.
- A review of the Other Dermatological Disorders products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Other Dermatological Disorders pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Other Dermatological Disorders.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Other Dermatological Disorders pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Other Dermatological Disorders - Pipeline Review, H1 2013
Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Other Dermatological Disorders Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Other Dermatological Disorders 7
Other Dermatological Disorders Therapeutics under Development by Companies 9
Other Dermatological Disorders Therapeutics under Investigation by Universities/Institutes 10
Mid Clinical Stage Products 11
Comparative Analysis 11
Early Clinical Stage Products 12
Comparative Analysis 12
Pre-Clinical Stage Products 13
Comparative Analysis 13
Other Dermatological Disorders Therapeutics - Products under Development by Companies 14
Other Dermatological Disorders Therapeutics - Products under Investigation by Universities/Institutes 15
Companies Involved in Other Dermatological Disorders Therapeutics Development 16
MIKA Pharma GmbH 16
TransDerm, Inc. 17
Other Dermatological Disorders - Therapeutics Assessment 18
Assessment by Monotherapy Products 18
Assessment by Route of Administration 19
Assessment by Molecule Type 21
Drug Profiles 23
MK-52 - Drug Profile 23
Product Description 23
Mechanism of Action 23
RandD Progress 23
MK-51 - Drug Profile 24
Product Description 24
Mechanism of Action 24
RandD Progress 24
tarenflurbil - Drug Profile 25
Product Description 25
Mechanism of Action 25
RandD Progress 25
TD-101 - Drug Profile 26
Product Description 26
Mechanism of Action 26
RandD Progress 26
canakinumab - Drug Profile 27
Product Description 27
Mechanism of Action 27
RandD Progress 27
AVX-001 - Drug Profile 28
Product Description 28
Mechanism of Action 28
RandD Progress 28
Other Dermatological Disorders Therapeutics - Drug Profile Updates 29
Other Dermatological Disorders Therapeutics - Discontinued Products 30
Other Dermatological Disorders Therapeutics - Dormant Products 31
Other Dermatological Disorders - Product Development Milestones 32
Featured News and Press Releases 32
Jun 11, 2012: Kythera Presents Positive Results From Second European Phase III Trial Of ATX-101 For Reduction Of Submental Fat 32
Mar 05, 2012: KYTHERA Initiates Pivotal US Phase III Clinical Trials To Evaluate ATX-101 For Reduction Of Submental Fat 33
Dec 14, 2011: Kythera Biopharmaceuticals Receives Notice Of Allowance For Additional US Patent On ATX-101 34
Jul 21, 2011: Merz Aesthetics Announces FDA Approval Of XEOMIN For Temporary Improvement In Appearance Of Moderate To Severe Glabellar Lines In Adult Patients 35
Apr 27, 2011: FDA Panel Recommends Lip Indication for Medicis's RESTYLANE 35
Jan 05, 2011: Amira Announces Publication Of AM095 Preclinical Results In Journal Of Pharmacology And Experimental Therapeutics 36
Dec 20, 2010: Fibrocell Submits Complete Response To FDA Regarding Azficel-T 36
Nov 24, 2010: Basilea Reports Toctino Included In Guidelines For Management Of Hand Eczema In Canada 37
Oct 26, 2010: NovaBay Reports New Data From Clinical And Preclinical Studies With NVC-422 38
Oct 15, 2010: NovaBay To Present Human Clinical Data On NVC-422 At IDSA Annual Meeting 39
Appendix 40
Methodology 40
Coverage 40
Secondary Research 40
Primary Research 40
Expert Panel Validation 40
Contact Us 41
Disclaimer 41



List of Tables

Number of Products Under Development for Other Dermatological Disorders, H1 2013 7
Products under Development for Other Dermatological Disorders - Comparative Analysis, H1 2013 8
Number of Products under Development by Companies, H1 2013 9
Number of Products under Investigation by Universities/Institutes, H1 2013 10
Comparative Analysis by Mid Clinical Stage Development, H1 2013 11
Comparative Analysis by Early Clinical Stage Development, H1 2013 12
Comparative Analysis by Pre-Clinical Stage Development, H1 2013 13
Products under Development by Companies, H1 2013 14
Products under Investigation by Universities/Institutes, H1 2013 15
MIKA Pharma GmbH, H1 2013 16
TransDerm, Inc., H1 2013 17
Assessment by Monotherapy Products, H1 2013 18
Assessment by Stage and Route of Administration, H1 2013 20
Assessment by Stage and Molecule Type, H1 2013 22
Other Dermatological Disorders Therapeutics - Drug Profile Updates 29
Other Dermatological Disorders Therapeutics - Discontinued Products 30
Other Dermatological Disorders Therapeutics - Dormant Products 31



List of Figures

Number of Products under Development for Other Dermatological Disorders, H1 2013 7
Products under Development for Other Dermatological Disorders - Comparative Analysis, H1 2013 8
Products under Development by Companies, H1 2013 9
Products under Investigation by Universities/Institutes, H1 2013 10
Mid Clinical Stage Products, H1 2013 11
Early Clinical Stage Products, H1 2013 12
Pre-Clinical Stage Products, H1 2013 13
Assessment by Monotherapy Products, H1 2013 18
Assessment by Route of Administration, H1 2013 19
Assessment by Stage and Route of Administration, H1 2013 20
Assessment by Molecule Type, H1 2013 21
Assessment by Stage and Molecule Type, H1 2013 22

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.